Decipher the Biology of Lethal Prostate Cancer - Urine Metabolomics Profiling in Men Receiving Prostate Biopsy and Men With Diagnosed Prostate Cancer Receiving MCS Supplementation

Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.

Start Date01 Aug 2017

Sponsor / Collaborator

National Taiwan University Hospital

[+8]

ISRCTN10431469

/ CompletedNot ApplicableIIT

Cognitive impAiRmEnt Study: Supplementation with the macular carotenoids, vitamin E and fish oil

Start Date04 Jan 2016

Sponsor / Collaborator-

NCT01003171

/ Unknown statusPhase 1

An Open-Label, Multiple-Dose Study of MCS-2 to Examine the Pharmacokinetics of MCS and Other Components After Once-daily Oral Dosing in Healthy Adult Volunteers

This study is to examine the pharmacokinetics, absorption and serum concentrations of MCS and other components after once-daily oral dosing of MCS.

Start Date01 Aug 2011

Sponsor / Collaborator

Health Ever Bio-Tech Co., Ltd.

100 Clinical Results associated with MCS-2

100 Translational Medicine associated with MCS-2

100 Patents (Medical) associated with MCS-2

101

Literatures (Medical) associated with MCS-2

01 Jul 2025·POULTRY SCIENCE

Music intervention mitigates LPS-induced gut barrier disruption and immune stress in broilers via TLR4/NF-κB regulation

Article

Author: Guo, Lu ; Chang, Qingqing ; Bao, Jun ; Li, Jianhong ; Zhang, Haoran ; Wang, Haowen ; Gong, Haiyue ; Jin, Shengzi ; Zhang, Jiaqi ; Zhang, Runxiang

Immune stress induced by harsh environment in intensive farming can impair broiler intestinal health. Although music as an environmental intervention can alleviate short-term stress injury, its long-term regulatory mechanism on intestinal inflammation has not been clarified. In this study, we investigated the effects of a music-enriched environment on growth performance, intestinal barrier function, and inflammatory responses in lipopolysaccharide (LPS)-induced immunostressed broilers. AA broilers were randomly divided into four groups: control group (CON), music-enriched environment group (MUC), LPS-induced immune stress group (LPS) and music-enriched environment + LPS group (MUC+LPS). On the 14th, 16th and 18th days, the LPS and MUC+LPS groups were injected intraperitoneally with 500 μg of LPS to construct an immune stress model, and the CON and MUC groups were injected with an equal amount of saline. On day 28, the birds were sacrificed to detect the indicators associated with intestinal barrier and inflammation. The LPS group showed a significant decrease in performance from 14 to 28 days, with elevated serum levels of CORT, ACTH, DAO, and d-LA, and a decrease in the activity of intestinal mucosal SOD/GSH-Px, and impaired gut morphology. impaired; music remission significantly alleviated the decline in production performance, reduced the levels of stress hormones and markers of intestinal barrier damage, while elevating jejuno-ileal GSH-Px activity and improving intestinal morphology. Significant inflammatory gene expression characteristics were observed in jejunum and ileum tissues after LPS injection: upregulation of TLR4, NF-κB, TNF-α, IL-1β, and IL-6, and significant suppression of jejunal IL-10 expression. Notably, IL-10 and IFN-γ expression in the ileum did not show statistical differences. Inflammation-related gene expression showed an overall down-regulation trend after the music intervention, but was still significantly different from the control group. Music intervention on the regulation of jejunal MYD88 and ileal TNF-α - the LPS group did not show statistically significant differences in the expression of these two key inflammatory nodes with the LPS+MUS group. Mechanistic studies have shown that LPS triggers an oxidative stress cascade through activation of the TLR4/NF-κB signaling axis, leading to disruption of intestinal barrier integrity. In contrast, music exposure exerts a protective effect through a dual mechanism: on the one hand, it helps to enhance the expression of the tight junction protein ZO-1/Occludin to repair the physical barrier; on the other hand, it inhibits the activation of the TLR4/NF-κB pathway, which can effectively alleviate LPS-induced immunopathological damage.

01 Jan 2025·INTERNATIONAL JOURNAL OF MEDICINAL MUSHROOMS

Quantitative LC-QToF-MS Analysis of Mycochemicals in Amanita muscaria, Psilocybe spp. (Agaricomycetes), and Consumer Products

Article

Author: Chittiboyina, Amar G ; G. Chittiboyina, Amar ; Avula, Bharathi ; Khan, Ikhlas A ; A. Khan, Ikhlas ; Lata, Hemant ; Katragunta, Kumar

The psychedelic mushroom market has expanded rapidly due to changing regulations and increasing consumer demand. Product diversity now extends beyond traditional capsules and tablets to include gummies, powders, and confectionery items, complicating quality control efforts. To assess the quality and potential adulteration of Amanita musca-ria and Psilocybe cubensis-based products, a validated LC-QToF-MS method was developed. This method focused on five characteristic compounds: ibotenic acid (IBA), muscimol (MUS), muscarine, psilocin, and psilocybin that are constituents of A. muscaria and P. cubensis mushrooms. Method validation demonstrated satisfactory linearity, precision, and recovery of all five analytes. Psilocin and psilocybin levels ranged from 0.001-1.6% and 9.9-19.3%, respectively, in five Psilocybe species samples, while IBA, MUS, and muscarine levels in two samples of Amanita muscaria were 0.03-0.04%, 0.01- 0.02%, and 0.01-0.02%, respectively. By comparing commercial products to authentic samples, we evaluated the overall quality of 27 across various formulations. Our analysis included 14 gummies, three chocolates, six capsules, one tablet, and three powders. Although 11 of 14 gummies claimed to contain Amanita mushroom extracts, only MUS and muscarine were detected, without IBA. Interestingly, one gummy product indicated the presence of psilocin and psilocybin despite the labeling that claimed, "no psilocybin." Eleven products contained psilocin and psilocybin as anticipated, but five products lacked all target compounds. These findings underscore the need for standardized product specifications. Nevertheless, the established LC-QToF-MS approach could serve as a valuable tool for evaluating the quality of magic mushroom-based consumer products.

04 Dec 2024·JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Unveiling the Potential Prebiotic Effects of Edible Mushroom Pleurotus djamor During In Vitro Colonic Fermentation

Article

Author: Medeiros, Rossana Lucena de ; de Albuquerque, Thatyane Mariano Rodrigues ; Zárate-Salazar, Jhonatan Rafael ; Pereira, Fillipe de Oliveira ; dos Santos Lima, Marcos ; Souza, Evandro Leite de ; Andrade, Giuliane Moura ; Tavares, Josean Fechine ; Oliveira, Jordana Nunes de

The ability of edible mushrooms to modulate the intestinal microbiota is a topic of interest. This study shows that digested Pleurotus djamor powder (MUS) exhibits prebiotic effects during an in vitro colonic fermentation. Phenolic compounds, including epicatechin (3.03 ± 1.54 mg/L), gallic acid (2.71 ± 1.54 mg/L), and quercetin 3-glucoside (2.40 ± 1.54 mg/L), were found in P. djamor. MUS significantly increased the relative abundance of Lactobacillus spp./Enterococcus spp. (1.12% - 4.83%), Bifidobacterium spp. (0.59% - 1.85%), Ruminococcus albus/R. flavefaciens (0.37% - 1.88%), and reduced Clostridium histolyticum (2.89% - 1.22%) during 48 of colonic fermentation. MUS enhanced lactic acid and short-chain fatty acid production and decreased pH levels. The ¹H NMR analysis revealed the presence of essential amino acids, branched-chain amino acids, and other compounds that benefit human health. The results indicate the prebiotic effects of P. djamor on human intestinal microbiota.

News (Medical) associated with MCS-2

24 Nov 2025

·www.globenewswire.com

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the “LOI”) with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech’s plant-derived new drug MCS-2for the Korean market. The prospective partner is a recognized supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea. This engagement is consistent with Jyong Biotech’s co‑commercialization strategy to collaborate with regional partners that offer established sales networks and local regulatory expertise. Definitive terms are being negotiated between the parties and the partnership, if such definitive terms will be agreed upon, would aim to leverage the partner’s commercial infrastructure to accelerate market access and patient reach in Korea. The LOI is non‑exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and other closing conditions. Fu Feng Kuo, Chairwoman of Jyong Biotech, commented: “A selective co‑commercialization approach with strategic partners will enable broader and faster patient access by combining its product development capabilities with partners’ commercial scale and local market knowledge. The Company will work to advance LOI negotiation with these strategic partners and provide updates as material developments occur.” As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/. Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: Jyong Biotech Ltd.ir@jyongbio.com Investor RelationsWFS Investor Relations Inc.Email: services@wealthfsllc.comPhone: +1 628 283 9214

License out/in

24 Nov 2025

·www.globenewswire.com

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Nov. 20, 2025 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP). The Company has completed the statistical analysis of the primary efficacy endpoints in its ongoing Phase II clinical trial conducted in Taiwan, following the randomized and placebo-controlled trial conducted to over 700 high-risk subjects enrolled into the Phase II clinical trial since its commencement. The data indicated that, compared with placebo, MCS-8 (PCP) demonstrated lower incidence rates of prostate cancer and high-grade prostate cancer (Total Gleason Score ≥ 7) with good overall tolerability, which lays an important foundation for potential future multinational Phase III clinical trials. The MCS-8 (PCP) Phase II study was a randomized, placebo-controlled trial conducted across 20 hospitals in Taiwan with participation from over 130 urologists—representing more than one-tenth of all urologists nationwide. The trial enrolled more than 700 high-risk subjects, each receiving two years of treatment (either MCS-8 (PCP) or placebo). Primary efficacy endpoint: Compared with placebo, the MCS-8 group indicated a 27.3% reduction in prostate cancer incidence. Secondary efficacy endpoint: Based on maximum Gleason score, the incidence of high-grade prostate cancer (Total Gleason Score ≥ 7) showed a 17.1% reduction compared with placebo. Safety assessments also showed: Two-year administration of MCS-8 did not increase adverse event rates, No serious adverse events related to MCS-8 were observed, No negative impact on liver function (AST, ALT), kidney function (BUN, Creatinine), fasting glucose, or blood pressure (systolic/diastolic). Moreover, in the placebo group, fasting glucose significantly increased (P = 0.022), and the triglycerides (TG), LDL, and HDL showed no significant differences. However, in the MCS-8 group, observed favorable lipid-modulating trends after two years of treatment compared with baseline: TG decreased (P = 0.05) LDL significantly decreased (P = 0.018) HDL significantly increased (P = 0.003) The Company believes that these findings highlight the safety and tolerability of MCS-8 and suggest that there might be potential for future clinical studies in lipid management, atherosclerosis, and cardiovascular diseases. Throughout the development of MCS-8 (PCP), the Company has adhered closely to U.S. FDA guidelines and standards, conducting rigorous scientific validation and clinical testing. “These positive results affirm the potential of MCS-8 (PCP) as a compelling candidate for prostate cancer prevention,” said Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “With good safety and efficacy signals, we are now preparing for the next stage of development. Our objective is to initiate a global Phase III trial, in collaboration with international pharmaceutical companies to further validate its clinical potential.” MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

17 Sep 2025

·www.globenewswire.com

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Sept. 16, 2025 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has completed patient enrollment in its Phase II clinical trial of MCS‑8, an investigational drug candidate for prostate cancer prevention (PCP), with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement. The randomized, placebo-controlled trial is being conducted across 20 hospitals in Taiwan, with the participation of more than 130 urologists. “We are pleased to have reached this key milestone in the MCS‑8 development program,” said Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “We have enrolled over 700 participants in this clinical trial, and despite the challenging times of the COVID-19 pandemic, we have successfully achieved this milestone and the progress has been ahead of our expectations. This truly reflects the team's professionalism, patience, dedication, and commitment.” MCS‑8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. The Company expects to analyze the trial data following completion of the treatment period and will share results in accordance with applicable disclosure requirements. Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

100 Deals associated with MCS-2

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lower Urinary Tract Symptoms	NDA/BLA	United States	Health Ever Bio-Tech Co., Ltd.	-
Prostatic Hyperplasia	NDA/BLA	United States	Health Ever Bio-Tech Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01002664 (GlobeNewswire) Manual	Phase 3	Prostatic Hyperplasia	302	BOTRESO	piimzmsvam(yhlhgwigcc) = no significant difference between groups in the U.S. subgroup and statistically significant improvement in the Asian subgroup (Taiwan) and the pooled Taiwan-U.S. population compared to placebo. vxlpinferv (omwrmjeruk ) View more	Positive	22 Aug 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MCS-2

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation